TNFR1-IN-2
TNFR1-IN-2 is a selective TNFR1 inhibitor with a Kd of 0.1 nM for hTNFR1. TNFR1-IN-1 inhibits TNFα-induced NF-κB signal transduction, with an IC50 value of 2.8 nM. TNFR1-IN-1 can be used in research related to inflammatory and immune diseases.
For research use only. We do not sell to patients.
- CAS No.: 3053449-34-3
- Formula: C104H124ClN21O22S
- Molecular Weight:2087.74
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
TNFR1 0.1 nM (Kd) |
TNFR2 >1000 nM (Kd) |
In Vitro
TNFR1-IN-2 (Seq ID NO.183) inhibits TNFR1, with a Kd of 0.1 nM for hTNFR1 and a Kd of >1000 nM for hTNFR2[1].
TNFR1-IN-2 (preincubated for 1 h, then co-incubated with TNFα for 16-18 h) inhibits TNFα-induced NF-κB signaling in THP-1 cells, with an IC50 value of 2.8 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 3053449-34-3
-
Molecular Weight 2087.74
-
Formula C104H124ClN21O22S
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)